

ASX ANNOUNCEMENT

30 October 2019

Cynata Corporate Presentation

Melbourne, Australia; 30 October 2019: Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), today released a presentation Cynata CEO, Dr Ross Macdonald, will use with investors to update on recent progress and public announcements.

-ENDS-

 CONTACTS:
 Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com

 Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus[™], a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus[™] MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.



A Next Generation Stem Cell Therapeutics Company

Investor Presentation: Cynata Therapeutics Limited October 2019



Important Information

This presentation has been prepared by Cynata Therapeutics Limited. ("Cynata" or the "Company") based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision.

This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Cynata, nor does it constitute financial product advice or take into account any individual's investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Cynata Therapeutics and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Cynata Therapeutics is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Cynata Therapeutics securities.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Cynata Therapeutics, its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

The information presented in this presentation is subject to change without notice and Cynata Therapeutics does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation.

The distribution of this presentation may be restricted by law and you should observe any such restrictions.

Forward looking statements

This presentation contains certain forward looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Cynata to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the political and economic environment in which Cynata will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Cynata and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

Cynata Therapeutics is a Phase II-ready biotech with a highly scalable, proprietary platform for developing stem cell therapeutics

Our focus

Utilise our proprietary Cymerus[™] platform technology to develop commercially scalable cellular therapeutic products to treat serious chronic disorders

About Cynata Therapeutics

- Cynata is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus, using discoveries made at the University of Wisconsin-Madison
- Cynata has licensed its first product, CYP-001 for graft-versus-host-disease (GvHD) to Fujifilm, with the intention to license Cymerus technology across a range of serious disorders
- Cynata's proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale

Financial information


A\$1.32	
102.8m	
A\$135.7m ~(US\$92.8m)	
A\$9.2m -	
A\$126.5m	
A\$126.5m	
A\$126.5m 9.3% 7.9%	



2019 Highlights: Driving Clinical and Commercial Success

Solution Fujifilm license	 Phase II GvHD trial funded by Fujifilm 	Progressing Osteoarthritis to Phase II trial
 Fujifilm exercised license option for CYP-001 in (GvHD) Future development of CYP-001 being funded entirely by Fujifilm US\$3m upfront payment to Cynata + milestones + royalties 	 Fujifilm to fund CYP-001 development and commercialisation with a Phase II clinical trial expected to commence in CY2020 	 Advancing towards 448 patient Phase I clinical trial Funded by the National Health and Medical Research Council
Fujifilm endorsement validates Cynata's Cymerus platform	Phase II trial expected to commence in CY2020	Phase II trial expected to commence in Q1 CY2020
 Progressing CLI to Phase II trial 	Advanced pre-clinical program	 Active commercial discussions
 Critical Limb Ischaemia (CLI): major clinical challenge and unmet need Severely impaired blood flow in the arteries: typically legs Clinical Trial Authorisation application filing expected imminently 	 Cymerus platform has therapeutic potential in numerous additional target areas of chronic disease Multiple preclinical studies successfully completed and data published 	 Executing on the Company's commercial plan to unlock the value of its platform technology across a broad range of indications
Phase II trial expected to commence in early CY2020	Therapeutic potential in numerous additional target areas	Focus on early commercialisation of Cynata's Cymerus MSC products

Cynata's Cymerus platform has potential applications across a wide range of diseases




Cynata has the only platform in the world to produce commercial quantities of MSCs from a single source






Value inflection point following clear data and first commercial transaction





Cynata is targeting significant market opportunities




2. ClearView's estimate of the peak annual global sales opportunity

3. Persistence Market Research 2018 research report: "Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)

Production and manufacturing process Our patented Cymerus platform enables the production of iPSC-derived cellular therapeutics from a single adult donor






- Induced pluripotent stem cells derived directly from adult cells and can propogate indefinitely
- Give rise to every other cell in the body creating a huge opportunity in regerative medicine
- Discovery of iPSCs awarded the Nobel Prize in Medicine in 2012

- Cynata's patented process
- Cymerus is the only platform in the world able to produce commercial quantities of Mesenchmal Stem Cells (MSCs) from a single source: iPSCs
- Mesenchymoangioblasts (MCAs) are produced from iPSCs and are readily able to expand and proliferate
- Bypasses complex and invasive surgeries and excessive MSC expansions with a scalable and cost effective process
- Overcomes regulatory hurdle as limitless quantites can be produced from a single donor

- MSCs have broad therapeutic potential
- Most widely studied type of adult stem cell, with potential treatments for a wide range of diseases






GvHD clinical trial results Highly successful outcome, with majority of patients reporting a Complete Response from a devastating disease



Phase I clinical trial data – all endpoints achieved¹



Patient data



No treatment-related serious adverse events or safety concerns were identified

www.cynata.com

1. Pooled Cohort A/B results at 100 days. 2. Absence of GvHD. 3. Overall Response is either a Complete or Partial Response (improvement by 1+ grade). 4. One patient in Cohort A died of pneumonia (unrelated to treatment), one patient in cohort B withdrew from trial on Day 22 to commence palliative care. **Fujifilm licensing agreement** Cynata is executing on a clear scientific and commercial vision and continually assesses pathways to optimise shareholder value



Multiple options to create shareholder value

Build value in platform independently (e.g. continue running clinical trials)

License / partner with big Pharma to develop specific target areas (e.g. Fujifilm license for GvHD)

> Strategic exit/merger (e.g. Strategic acquirer)


FUJIFILM case study

- ✓ Exclusive global licence in GvHD
- ✓ Multiple cash flow events:
 - US\$3m equity @ 35% premium
 - US\$3m upfront license fee received
 - <u>US\$40m</u> in potential milestone payments
 - Double digit royalties (worth potentially >US\$30m p.a.)
- ✓ Represents a major endoresement by Big Pharma
- ✓ Ongoing relationship with potential for further commercial agreements

FUJIFILM transaction provides validation of the Cymerus platform and supports the licensing of additional target areas



New enhanced pipeline and clear pathway to commercialisation




Fujifilm's estimate of the peak annual global sales opportunity

www.cvnata.com

2. ClearView's estimate of the peak annual global sales opportunity

3. Persistence Market Research 2018 research report: "Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)."

Pipeline and Catalysts Cynata has a large pipeline of indications with upcoming catalysts







Globally experienced board and management team



Dr Paul Wotton Chairman

- CEO. Obsidian Therapeutics
- Former CEO of Ocata Therapeutics (NASDAQ: OCAT) acquired by Astellas Pharma, in a US\$379m transaction
- Previous executive roles with Antares Pharma Inc. (NASDAQ: ATRS), Topigen Pharmaceuticals and SkyePharma
- Founding CEO, Sigilon Therapeutics; board member of Vericel Corp and Veloxis: past Chairman of the Emerging Companies Advisorv Board of BIOTEC Canada
- **Expertise running and** monetising Ocata Therapeutics, acquired by Astellas



Dr Ross Macdonald Managing Director / CEO

30 years' experience

and a track record of

pharmaceutical and

management positions

with Hatchtech, Sinclair

Connetics Corporation

Stiefel Laboratories. the

success in

businesses

•

biotechnology

Previous senior

Pharmaceuticals.

(Palo Alto, CA), and

largest independent

in the world and

for f2 25b

dermatology company

acquired by GSK in 2009

Dr Stewart Washer Non-Exec Director

20+ years of CEO and Board experience in

medical technology.

biotech and agri-food

Chairman of Orthocell

Ltd. Director of Botanix

Exec Chairman of

Emerald Clinics.

Ltd and Zelda

Therapeutics Ltd

Previously CEO roles

with Calzada (ASX:CZD),

Phylogica (ASX:PYC) and

Celentis and managed

the commercialisation

of intellectual property

New Zealand with 650

Scientists and \$130m

revenues

from AgResearch in

companies



Dr Geoff Brooke Non-Exec Director

- 30+ vears venture capital experience
- Co-founded GBS Venture Partners
- Formerly President of Medvest. a US-based early-stage venture capital group he founded with Johnson & Johnson
- Other Board experience include non-executive director of Acrux Limited and Chairman of Actinogen Media Limited



Mr Peter Webse Non-Exec Director **Company Secretary**

- +25 years' company secretarial experience
- Managing Director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services



Dr Kilian Kelly Chief Operating Officer

- 15 years' experience in pharmaceutical / biotechnology research and development, in both commercial and academic settings
- Previous appointments include Senior Director, Drug Development at **Biota Pharmaceuticals** (NASDAQ: BOTA). Vice President, Regulatory and Clinical at Mesoblast Limited (ASX:MSB)

Track record of success in pharmaceutical and biotechnology businesses

Deep experience growing companies as CEO and on the Board

Extensive life sciences and financial expertise in **US and Australia**

25+ years company secretarial and management experience **Extensive academic.** commercial and management experience



Scalable, globally applicable technology	 Cymerus platform technology enables commercial-scale production of mesenchymal stem cells Fully patented process overcomes multiple issues with today's on-market solutions Value of platform to a range of diseases demonstrated across multiple clinical and pre-clinical studies
2 Attractive licensing business model	 A 'hub and spoke' model: intention to license Cymerus technology across a range of target areas Licence granted to FUJIFILM for GvHD on highly attractive terms, including US\$3m upfront fee, >US\$40m in milestone payments, double digit royalties on product sales and FUJIFILM responsible for all further product development activities and costs Cynata in active commercial discussions with multiple other parties
3 Successful clinical trial results	 First in-human trial of Cymerus MSCs in GvHD successfully completed in 2018 All trial endpoints achieved: no safety concerns identified; highly encouraging efficacy Endorsement by FUJIFILM of Cynata's Cymerus platform supports the continued commercialisation of Cynata's cell therapeutic products in other indications
4 Clear pipeline of high potential target areas	 Phase II clinical trial program commencing in Critical Limb Ischemia (CLI) in 2020 Phase II clinical trial in Osteoarthritis (OA) commencing in 2020, funded by NHMRC Phase II clinical trial in GvHD commencing in 2020 (Fujifilm) Compelling pre-clinical data in multiple other high-value target areas supports further clinical trials
5 Well positioned in regenerative medicine	 Cell therapeutics is an area of increasing interest from major pharmaceutical companies Global market opportunity of US\$1.4bn for CLI and US\$11.6bn for OA Over 930 clinical trials investigating the efficacy of MSCs in treating diseases have been initiated globally



Thank you for your attention

Cynata Therapeutics Limited

Level 3 62 Lygon Street Carlton Victoria 3053 Australia

Contact details:



ross.macdonald@cynata.com



www.cynata.com





Appendix



Critical Limb Ischemia | Overview of Cynata-led Phase II program

Estimated market size	230,000 Addressable events per year	~US\$1.4B¹ Forecast annual global market sales		
Critical Limb Ischemia (CLI)	 MSC therapy for effective treatment of critical limb ischemia patients who are ineligible for revascularization, to promote angiogenesis and reduce inflammation 			
Rationale for selection	 Cymerus preclinical studies were compelling, animals treated with Cymerus MSCs experienced improved blood flow (p<0.006) and faster blood flow recovery (p<0.001) when compared to the control group treated with saline Development timeline is relatively rapid 			
Preliminary program design	 Pivotal trials may last 1–2 years and require 50–100 revascularisation-ineligible patients (patients not eligible for surgery intended to restore blood flow) Endpoints likely to include amputation-free survival and ankle-brachial index, ulcer healing, and pain (reviewed over 6–12 months) 			
Image: state Image: state Image: state Image: state Image: state Image: state Key milestones	 Planning for Phase II program in Critical Lim to begin in early CY2020 	nb Ischemia has commenced; trial expected		



Estimated market size		30,000,000 People in the USA affected by osteoarthritis	~US\$11.6B¹ Forecast global market opportunity by 2025		
ł	Osteoarthritis	 Assess the effect of Cymerus MSCs on clinical outcomes and knee joint structures of patients with osteoarthritis of the knee (compared to a placebo) 			
	Rationale for selection	 Preclinical research showed MSCs can exert a number of important effects, including release of cytokines and growth factors that reduce inflammation and promote tissue repair, new blood vessel formation, and regeneration of compromised cartilage which may result in improved outcomes for patients 			
<u>~</u>	Preliminary program design	 448-patient trial funded by an NHMRC project grant and in-kind contributions from participating institutions (no cash contribution from Cynata) Cynata to supply Cymerus MSCs for use in the trial² and will retain full commercial rights to the use of Cymerus MSCs in osteoarthritis 			
	Key milestones	Phase II clinical trial in Osteoarthritis expect	ted to commence in 1Q CY2020		

Persistence Market Research 2018 research report: "Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)."
 Subject to ethics/regulatory approval and execution of a satisfactory material transfer agreement with the University of Sydney



Pre-clinical studies | Ongoing value-creating program

Pre-clinical studies are intended to provide a rational basis for investigating the potential safety and efficacy of an experimental drug in particular disease indications

Demonstrate	 MSCs have already shown promising therapeutic potential in a wide range of
potential of MSCs	pre-clinical models (as well as in human patients)
Validate Cymerus	 Cynata has sought to collaborate with experts in various therapeutic areas to
technology	validate the potential clinical utility of the Cymerus technology
Cost-effective	 An important element has been to leverage expenditure as much as possible through grants and joint projects

The successful outcomes from these studies, combined with the clinical data in GvHD have facilitated a number of ongoing commercial discussions in these and other clinical indications



Pre-clinical studies | Existing target areas

Disease target area	Partner	Pre-clinical trials started	Proof of concept completed	Key highlights	Global market opportunity*
ARDS	Critical Care RESEARCH GROUP	1		Study to commence to evaluate effectiveness of Cymerus MSCs in sheep with ARDS in association with the Prince Charles Hospital in Brisbane.	US\$2.5bn by 2018 ²
Heart attack	THE UNIVERSITY OF SYDNEY	✓	√	Data indicates that Cymerus MSCs may have the potential to restore cardiac function and reduce scar size after a heart attack	US\$18.2bn by 2019 ³
Brain Cancer / Glioblastoma		✓	√	Research collaboration in genetically modified MSCs in cancer: involves modifying stem cells to target cancer	US\$3.3bn by 2024 ⁴
Diabetic Wounds	Cell Therapy Manufacturing	✓	√	Independent study by CRC for Cell Therapy Manufacturing generated positive data which demonstrates the efficacy of Cymerus MSCs in a preclinical model of diabetic wounds	US\$4.9bn by 2024⁵
Coronary Artery Disease		✓	√	Research collaboration for the development of MSC therapies to treat coronary artery disease	US\$22.5bn by 2021 ⁶
Asthma	MONASHUnversity	✓	√	Cymerus MSCs demonstrated significant beneficial effects on three key components of asthma: airway hyper-responsiveness, inflammation and airway remodelling	US\$25.6bn by 2024 ¹
Cytokine Release Syndrome	University of Massachusett Amherst	s 🗸	✓	Pre-clinical model demonstrating Cymerus MSCs significantly ameliorate the effects of Cytokine Release Syndrome, a potentially severe and life-threatening adverse reaction to cancer immunotherapy	US\$4.5bn by 2022 (CAR-T) ⁷
Sepsis	RCSI	✓		Development partnership with RCSI (Royal College of Surgeons in Ireland), one of the foremost health sciences research institutions in Europe, to investigate the utility of Cymerus MSCs in sepsis, the leading cause of death in ICU's	US\$5.9bn by 2026 ⁸

Successful outcomes open many other disease targets potentially benefiting from MSCs

Notes

*Reflects total global market opportunity for the relevant therapeutic category

1. Grand View Research, 2016; 2. Vasomune Therapeutics company announcement, 2018 3. GBI Research, 2013; 4. Global Data, 2016; 5. Transparency Market Research, 2018; 6. Smithers Apex, 2015; 7. Evaluate Pharma, 2017; 8. GlobalData 2017